In this issue of Deep Dive we explore the ever present issues of market access and commercialisation, analysing recent changes in China, England and the US and asking how pharma can work wi
As it continues to look into drugs that can help opioid-dependant patients, Sandoz has signed an agreement with Shionogi to commercialise Rizmoic (naldemedine) in the key European markets
Richard Francis is stepping down as CEO of Novartis’ generics and biosimilars division Sandoz at the end of March, sparking further speculation about the unit’s future.
A digital therapeutic for irritable bowel syndrome, a developing world disease diagnosis tool, and a mobile maternity clinic in Uganda, were the three winners of Sandoz’s competition to imp
